目次

Table of Contents

List of Tables

List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatic Encephalopathy - Overview
Hepatic Encephalopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hepatic Encephalopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatic Encephalopathy - Companies Involved in Therapeutics Development
Alfasigma SpA
Axcella Health Inc
Cosmo Pharmaceuticals NV
Grifols SA
Kaleido Biosciences Inc
Neuropathix Inc
Rebiotix Inc
Takeda Pharmaceutical Co Ltd
TenNor Therapeutics Ltd
Umecrine Cognition AB
Vedanta Biosciences Inc
Versantis AG
Hepatic Encephalopathy - Drug Profiles
albumin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
AXA-1665 - Drug Profile
Product Description
Mechanism Of Action
History of Events
golexanolone - Drug Profile
Product Description
Mechanism Of Action
History of Events
KB-174 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KLS-13019 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KLS-13023 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RBX-2660 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RBX-7455 - Drug Profile
Product Description
Mechanism Of Action
History of Events
rifamycin sodium CR - Drug Profile
Product Description
Mechanism Of Action
History of Events
rifaximin - Drug Profile
Product Description
Mechanism Of Action
History of Events
rifaximin SSD - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-039 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TNP-2092 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VE-303 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VS-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VS-02 - Drug Profile
Product Description
Mechanism Of Action
Hepatic Encephalopathy - Dormant Projects
Hepatic Encephalopathy - Discontinued Products
Hepatic Encephalopathy - Product Development Milestones
Featured News & Press Releases
Jan 18, 2022: Neuropathix receives patent grant from India for its novel anti-inflammatory compounds
Jan 11, 2022: Karolinska Development's portfolio company Umecrine Cognition presents preclinical data showing that golexanolone reduces neuroinflammation and counteracts motor symptoms
Nov 02, 2021: Axcella Therapeutics announces upcoming presentation of AXA1665 at AASLD's The Liver Meeting 2021
Jul 14, 2021: Karolinska Development's portfolio company Umecrine Cognition raises capital through a successful share issue
Jun 30, 2021: Axcella announces initiation of EMMPOWER phase 2 clinical trial of AXA1665
May 24, 2021: Positive clinical data about Axcella's AXA1665 candidate for overt hepatic encephalopathy highlighted in oral presentation at DDW 2021
Apr 22, 2021: Axcella announces upcoming oral presentation at digestive disease week (ddw) 2021
Apr 22, 2021: Karolinska Development's portfolio company Umecrine Cognition publishes clinical research results in a highly regarded journal
Dec 29, 2020: Karolinska Development increases book value of Umecrine Cognition by SEK 234 million
Oct 07, 2020: Kaleido Biosciences to present data from candidate KB174 at The Liver Meeting 2020
Oct 06, 2020: Kannalife adds to its global IP estate receiving patent grant from Canada for its novel anti-inflammatory compounds
Sep 02, 2020: Karolinska Development's portfolio company Umecrine Cognition presents results from clinical phase 2a study at AALSD International Liver meeting
Aug 27, 2020: Kaleido Biosciences announces presentation of data for microbiome metabolic therapy KB174 for Hepatic Encephalopathy at The Digital International Liver Congress (EASL)
Aug 25, 2020: Kannalife receives patent grants in additional European territories
Aug 05, 2020: Axcella reports positive top-line data from AXA1665-002
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hepatic Encephalopathy, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hepatic Encephalopathy - Pipeline by Alfasigma SpA, 2022
Hepatic Encephalopathy - Pipeline by Axcella Health Inc, 2022
Hepatic Encephalopathy - Pipeline by Cosmo Pharmaceuticals NV, 2022
Hepatic Encephalopathy - Pipeline by Grifols SA, 2022
Hepatic Encephalopathy - Pipeline by Kaleido Biosciences Inc, 2022
Hepatic Encephalopathy - Pipeline by Neuropathix Inc, 2022
Hepatic Encephalopathy - Pipeline by Rebiotix Inc, 2022
Hepatic Encephalopathy - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Hepatic Encephalopathy - Pipeline by TenNor Therapeutics Ltd, 2022
Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, 2022
Hepatic Encephalopathy - Pipeline by Vedanta Biosciences Inc, 2022
Hepatic Encephalopathy - Pipeline by Versantis AG, 2022
Hepatic Encephalopathy - Dormant Projects, 2022
Hepatic Encephalopathy - Discontinued Products, 2022

List of Figures
Number of Products under Development for Hepatic Encephalopathy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022